U.S. Army issues solicitation for filovirus countermeasure development project

Courtesy of opb.org
The U.S. Army Contracting Center recently issued a solicitation for a medical countermeasure (MCM) development and research project for filoviruses.

Filoviruses are the family of species that are responsible for the various strains of the Ebola virus and the Marburg virus.

The solicitation will be under full and open competition among qualified sources for this kind of work. The aim for the Joint Project Manager - Medical Countermeasure Systems - BioDefense Therapeutics (JPM-MCS-BDTx) in this solicitation is to procure an agreement for the research and development of MCMs for emerging diseases related to the Ebola and Marburg viruses that would ultimately obtain Food and Drug Administration (FDA) approval for use in biological defense applications and treatments for this kind of biological warfare agent.

Proposals from interested companies and other eligible entities will be required to submit all required materials to Natick Contracting Division by Wednesday, Jan. 20, 2016, at 4:30 p.m. ET. Questions should be submitted to contracting staff by Friday, Dec. 4.

Proposals will be evaluated based on the applicant’s ability to perform tasks associated with this solicitation and to offer the best value in terms of work and funding needs.

Organizations in this story

U.S. Army 8825 Beulah St Washington, DC 22060

Get notified the next time we write about U.S. Army!